Abstract: The invention is directed to a method of diagnosing a malignant ovarian tumor disease in a subject, which comprises —providing a sample of peripheral blood cells (PBC) of the subject, —measuring the expression of a multimarker gene panel comprising at least NEAT1, BC037918, C1 orf63, PRIC285, OSM, and optionally further genes or protein markers, and —comparing to a reference value, the differential expression being indicative of a malignant ovarian tumor, and a set of reagents to determine the expression of such a multimarker panel, as well as the use of a PBC-expression based test to improve the diagnosis of ovarian cancer. The invention further relates to a method of determining the expression of at least one of the RPL21, RPL9 and/or SH3BGRL3 genes in a PBC sample of a subject as internal control.

Abstract: A method of determining gynaecologic tumor disease in a subject by providing a sample of peripheral blood of the subject, measuring the PPIC expression of cells in the sample, and comparing this to a reference value, the PPIC overexpression being indicative of a gynecologic tumor disease and/or disease progression, including metastatic potential in a gynecologic cancer patient.

Abstract: A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms.